The design and synthesis of 1,4-substituted piperazine derivatives as triple reuptake inhibitors

Bulletin of the Korean Chemical Society

Volumn 33, Issue 8, 2012, Pages 2597-2602

  Han, Minsoo ^a,b   Han, Younghue ^a   Song, Chiman ^a   Hahn, Hoh Gyu ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

Author keywords

Antidepressants; CNS drug; Major depressive disorder; Piperazine; Triple reuptake inhibitor

Indexed keywords

ANTIDEPRESSANTS; CNS DRUG; MAJOR DEPRESSIVE DISORDER; PIPERAZINE; TRIPLE REUPTAKE INHIBITOR;

CHEMISTRY; SYNTHESIS (CHEMICAL);

NEUROPHYSIOLOGY;

EID: 84865251307     PISSN: 02532964     EISSN: 12295949     Source Type: Journal    
DOI: 10.5012/bkcs.2012.33.8.2597     Document Type: Article

References (25)

1. Prins, J.; Olivier B.; Korte, S. M. Expert Opin. Investig. Drugs 2011, 20(8), 1107.
2. Kulkarni, S. K.; Dhir, A. Expert Opin. Investig. Drugs 2009, 18(6), 767.
3. Millan, M. J. Neurotherapeutics 2009, 6, 53.
4. Skolnick, P.; Basile, A. S. Drug Discov. Today: Ther. Strat. 2006, 3(4), 489.
5. Holtzheimer, P. E., III.; Nemeroff, C. B. Neurotherapeutics 2006, 3, 42.
6. Zisook, S.; Rush, A. J.; Haight, B. R.; Clines, D. C.; Rockett, C. B. Biol. Psychiatry 2006, 59, 203.
7. Papakostas, G. I.; Worthington, J. J., III.; Iosifescu, D. V.; Kinrys, G.; Burns, A. M.; Fisher, L. B.; Homberger, C. H.; Mischoulon, D.; Fava, M. Depress. Anxiety 2006, 23, 178.
8. Fava, M. J. Clin. Psychiatry 2001, 62(18), 4.
9. Prica, C.; Hascoet, M.; Bourin, M. Behav. Brain. Res. 2008, 194, 92.
10. Beer, B.; Stark, J.; Krieter, P.; Czobor, P.; Beer, G.; Lippa, A.; Skolnick, P. J. Clin. Pharmacol 2004, 44(12), 1360.
11. Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. Life Sciences 2003, 73, 3175.
12. Chen, Z.; Skolnick, P. Expert Opin. Investig. Drugs 2007, 16(9), 1365.
13. Dömling, A.; Huang, Y. Synthesis 2010, 17, 2859.
14. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Curr. Opin. Chem. Biol. 2010, 14, 347.
15. Gray, D. L.; Xu, W.; Campbell, B. M.; Dounay, A. B.; Barta, N.; Boroski, S.; Denny, L.; Evans, L.; Stratman, N.; Probert, A. Bioorg. Med. Chem. Lett. 2009, 19, 6604.
16. Carter, D. S.; Cai, H.-Y.; Lee, E. K.; Iyer, P. S.; Lucas, M. C.; Roetz, R.; Schoenfeld, R. C.; Weikert, R. J. Bioorg. Med. Chem. Lett. 2010, 20, 3941.
17. Glowa, J. R.; Wojnicki, F. H. E.; Matecka, D.; Bacher, J. D.; Mansbach, R. S.; Balster, R. L.; Rice, K. C. Exp. Clin. Psychopharmacol. 1995, 3, 219.
18. Prisinzano, T.; Rice, K. C.; Baumann, M. H.; Rothman, R. B. Curr. Med. Chem.:Central Nervous Syst. Agents 2004, 4, 47.
19. Khan, A. Expert Opin. Investig. Drugs 2009, 18(11), 1753.
20. Kim, J. Y.; Kim, D.; Kang, S. Y.; Park, W.-K.; Kim, H. J.; Jung, M. E.; Son, E.-J.; Pae, A. N.; Kim, J.; Lee, J. Bioorg. Med. Chem. Lett. 2010, 20, 6439.
21. Kerns, E.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization; Elsevier: Amsterdam, 2008; p 122.
22. Pardridge, W. M. J. Neurochem. 1998, 70, 1781.
23. Pajouhesh, H.; Lenz, G. R. Neurotherapeutics 2005, 2, 541.
24. Sonda, S.; Kawahara, T.; Murozono, T.; Sato, N.; Asano, K.; Haga, K. Bioorg. Med. Chem. 2003, 11, 4225.
25. Jørgensen, S.; Nielsen, E. Ø.; Peters, D.; Dyhring, T. Journal of Neuroscience Methods 2008, 169, 168.